(Q33742346)

29 July 2017

Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (English)

1 reference

29 July 2017

1 reference

Moghadasian MH

1

1 reference

PubMed ID

10503952

29 July 2017

language of work or name

English

0 references

publication date

1 January 1999

1 reference

29 July 2017

1 reference

29 July 2017

65

1 reference

29 July 2017

1329-1337

1 reference

29 July 2017

13

1 reference

Defective cholesterol biosynthesis associated with the Smith-Lemli-Opitz syndrome

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900199-X

Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900199-X

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900199-X

Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900199-X

Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900199-X

Pharmacology of competitive inhibitors of HMG-CoA reductase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900199-X

Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900199-X

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900199-X

Cerivastatin, a New Potent Synthetic HMG Co-A Reductase Inhibitor: Effect of 0.2 mg Daily in Subjects With Primary Hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900199-X

Effect of pravastatin on outcomes after cardiac transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900199-X

Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900199-X

CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900199-X

An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900199-X

Physiological disposition of HMG-CoA-reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900199-X

Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900199-X

Interaction between fibre and lovastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900199-X

Pharmacokinetics of fluvastatin and specific drug interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900199-X

Effect of food on the bioavailability of atorvastatin, an HMG-CoA reductase inhibitor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900199-X

Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900199-X

Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900199-X

Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900199-X

Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900199-X

Fluvastatin in familial hypercholesterolemia: a cohort analysis of the response to combination treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900199-X

Pharmacokinetics of the combination of fluvastatin and gemfibrozil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900199-X

Rhabdomyolysis after taking atorvastatin with gemfibrozil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900199-X

Lovastatin, nicotinic acid, and rhabdomyolysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900199-X

Lovastatin. Warfarin interaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900199-X

Atorvastatin does not alter the anticoagulant activity of warfarin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900199-X

Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900199-X

More on rifampin prophylaxis against Haemophilus influenzae b in day-care facilities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900199-X

Lack of interaction between ramipril and simvastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900199-X

Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900199-X

Lack of interaction between fluvastatin and oral hypoglycemic agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900199-X

Simvastatin use in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900199-X

Treatment of hypercholesterolaemia in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900199-X

Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900199-X

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900199-X

Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900199-X

10.1016/S0024-3205(99)00199-X

7 January 2021

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10503952